SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

Nano Mobile Healthcare Inc. (VNTH)

VNTH RSS Feed
Add VNTH Price Alert      Hide Sticky   Hide Intro
Moderator: imgoingfishing1, ThoughtPower, Dr G Bucks, GC Investments
Search This Board: 
Last Post: 12/13/2017 4:12:00 PM - Followers: 192 - Board type: Free - Posts Today: 0


Partnernering with:

 


We are developing detection devices based on patented technology invented by the National Aeronautics and Space Administration (“NASA”) that was licensed to Nanobeak, and further sublicensed to us.
 

Effective as of February 20, 2014, our majority shareholder sublicensed to the Company rights acquired under a license agreement with the National Aeronautics and Space Administration (“NASA”) to certain inventions and patent rights owned by NASA relating to chemical sensing nanotechnology, for use within the United States and its territories. As a result of the sublicense, the Company is now a mobile health technology company that is developing personalized and point-of-care screening using applications based upon chemical sensing methods.
Our sublicense for the use of NASA technology has been extended by three years such that the exclusivity of the underlying patents now ends in 2021, providing us with the additional time we need to advance the healthcare applications when the law enforcement breathalyzer enters the marketplace. 

 

 

Nano Mobile Healthcare Inc.
 
Nano Mobile Healthcare (SEC name)  Vantage mHealthcare (ref. VNTH)

 
Business Description

Nano Mobile Healthcare - a mobile health technology company - is developing personalized and point-of-care screening using Apps based upon chemical sensing residing within a Bluetooth device that works with any smartphone, tablet or laptop. With its foundations in advanced nanotechnology, the Company's first product, the Nano Mobile Health Sensor, which is in development, is the convergence of nano-electronics, bio-informatics, and wireless technology to create the next generation mobile health application. The Company has offices in New York City and Mountain View, CA. For more information, please visit us at http://nanomobilehealthcare.com/.

 
 

 
 





 


Before the Vantage Sensor, NASA used the sensor technology to protect the astronauts from harmful gases.

The NASA sensor technology offers nine years of results on the Space Shuttle and the International Space Station.

"The sensor was Awarded the NASA Invention of the Year "
http://www.spacefoundation.org/programs/space-certification/certified-products/space-technology/nanobeak-sensor


 





'NANOBEAK Mobile (Stage 1 lung cancer detection) is the first sensor and app planned to be released in 2018.' - John Groman

NANOBEAK MOBILE TECHNOLOGY COVERS MULTIPLE PATENTS OF SCIENTIFIC DETECTIONS i.e. HEALTHCARE & LAW ENFORCEMENT  (re: SEC 10-K)

UPDATE :  Thu 4/20/2017 3:04 PM

"we are working diligently to get our filings current, as well as to move forward with news"  VNTH President J. Peters
(via an investor's email inquiry & quoted response)



UPDATES:
http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=12046187
 

UPDATE :  Friday, 05/26/17 09:36:39 AM

"just as we worked to get the recent 10K filed, we are working diligently to catch-up on all our filings"
J. Peters
(via an investor's email inquiry & quoted response)


COMPANY CONTACTS:

NanoBeak Development <development@nanobeak.com>  Team

http://nanomobilehealthcare.com/investors/investor-faqs


 


Age: 58

Education: West Scranton High School, 1975; bachelor’s degree, criminal justice, King’s College, 1979; juris doctor, Dickinson School of Law, 1983

Experience: Scranton police officer, 1978-1981; assistant, deputy and executive deputy attorney general with focus on organized crime and drugs, including as director of the Bureau of Narcotics Investigation, attorney general’s office, 1982-1998; director, federal high-intensity drug-tracking area, Philadelphia, 1998-1999; director, all federal high-intensity drug-trafficking areas, national drug czar’s office, 1999-2003; counterterrorism consultant, 2004-present; president and chief executive officer, Nano Mobile Healthcare Inc., 2014-present; president, MSGI Technology Solutions, Inc. (formerly, MSGI Security Solutions, Inc., Media Services Group), 2004-present; executive director, Scranton Cultural Center, 2011-2013; state executive deputy attorney general in charge of communications, 2013-2014.


http://www.businesswire.com/news/home/20140924005092/en/Vantage-Health-Announces-Appointment-Joseph-C.-Peters

http://www.otcmarkets.com/stock/VNTH/profile

Board Members Included as of May 30th 2017:

Robert Chicoski. Since 2004 Mr. Chicoski has been the acting CFO for two Boston-based businesses providing contract CFO services for all accounting, finance, tax and bank financing matters as well as other strategic business and corporate matters. From June 2012 through April 2017, Mr. Chicoski was the controller, acting Chief Financial Officer and Private Investor Mentor for GVP Global Corp, a Boston private equity investment company.  Mr. Chicoski has been a Certified Public accountant since 1969. He was the founder, Treasurer and Chief Financial Officer of a start- up company, World Energy Solutions, that was previously listed on the Over the Counter Exchange as XWES and subsequently acquired by EnerNOC in 2015. Mr. Chicoski received a BS in Accounting from Bentley College of Accounting and Finance.




James C. Katzaroff was appointed to serve as a member of the Company’s board of directors. James C. Katzaroff. Mr.  Katzaroff is the founder of Advanced Medical Isotope Corp. (Symbol: ADMD) and was the Chief Executive Officer from 2007 through December 2016.  Mr. Katzaroff continues to serve as a director of ADMD.  ADMD is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non-resectable tumors.   Mr. Katzaroff holds a Bachelor’s Degree in Business Economics from the University of California, Santa Barbara and has completed advanced management courses at the University of Washington.


AND

MEET OUR INVESTORS: NANOBEAK MAJOR INVESTOR

John Groman

CURRENT:   NANOBEAK Mobile (Stage 1 lung cancer detection) is the first sensor and app planned to be released in 2018.

John Groman's History Excerpt

Nanobeak History Summary

My (John Groman) latest venture is a private medical device company that has a non-invasive, sensor and app that will detect stage one lung cancer as well as other detections offered at the price of $1 per test (wholesale). The technology combines our exclusive NASA license of four issued patents and two pending patents with the biomarker research and human trial data from our medical partner Johns Hopkins along with our own proprietary IP. The Sensor and app provide results in real time and will work with all Smartphones, Tablets, Laptops and Desktops. 

Nanobeak, Inc, May 2013 - Present (4 years 1 month)
Bella Sante, Chairman & Founder  - December 1993 – Present (23 years 6 months)
Eames Capital Partners, LLC March 2013 – Present (4 years 3 months)
Epsilon - Co Founder and EVP November 1969 – January 2000 (30 years 3 months) Greater Boston Area Advertising and database marketing agency

Education
Harvard Business School
 

NANOBEAK IS THE PARENT COMPANY OF NANO MOBILE HEALTHCARE

Images and some literature is courtesy of http://nanomobilehealthcare.com/
 

NANOTECHNOLOGY

 

The Nano Mobile Sensor detects chemicals and Volatile Organic Compounds using Carbon Nanotubes.

The sensor was Awarded the NASA Invention of the Year :


http://www.spacefoundation.org/programs/space-certification/certified-products/space-technology/nanobeak-sensor
 

 
INFORMATION PROVIDED DIRECTLY FROM:
      THE NANO MOBILE HEALTHCARE 
    'NANOBEAK' Development Team

PARENT COMPANY: Vantage mHealthcare Inc. (VNTH)

 



NASA Technology Space Certification




http://www.spacefoundation.org/programs/space-certification/certified-products/space-technology/nanobeak-sensor

http://www.spacefoundation.org/programs/space-certification/certified-partners/certified-companies/nanobeak-nano-mobile-healthcare


 

Nano Mobile Healthcare is developing a sensor that will screen for the Volatile Organic Compound signatures in a person’s breath. Our device and application (working with any smart phone, laptop or tablet) will be able to identify the presence of lung cancer from a single exhalation. Results will be able to be viewed by patient and doctor in-the-moment and when treatment options are discussed. The Nano Mobile Sensor was developed to address one of the longest standing unmet medical needs today which involves early stage lung cancer detection and to do so in an affordable, non-invasive, safe and convenient way.

http://nanomobilehealthcare.com/



Imagine a World
 

 



 



 

Vantage Health News History
 

USA TODAY - The Future Of Health Care Is Social And Techie

http://www.usatoday.com/story/tech/columnist/shinal/2014/03/08/health-apps-sxsw-shinal/6205491/
 

ISSUU - Government Health Care United States Buyers Guide: Winter 2014

http://issuu.com/govworld/docs/govt._health_care_winter/10?e=0/6390099

Meditek - Could A Smartphone Detect Lung Cancer?

Mobile Health News - Scripps To Test NASA-Developed, Smartphone-Enabled Lung Cancer Sensor

http://mobihealthnews.com/29840/scripps-to-test-nasa-developed-smartphone-enabled-lung-cancer-sensor
 

Strategic Partnerships

We have entered into a strategic partnership with Theranostics Laboratory, a translational research company, with offices in the USA and New Zealand. Theranostics Laboratory was founded at the Cleveland Clinic in 2010 and works on subcontracted research, in collaboration with the Auckland Bioengineering Institute (ABI), in New Zealand, and with NASA (via NASA Grant NCC 9-58).

The Auckland Bioengineering Institute is recognized as a world-leader in the field of personalized modeling and is part of the international Virtual Physiologic Human (VPH) project. The Institute has successfully commercialized numerous mHealth technologies, including wireless telemetry systems, wearable sensors and a needle-free injectable system into the US market.

The partnership between the Theranostics Laboratory and the Auckland Bioengineering Institute (ABI) is a strategic alliance for us through which the lab will act as principal investigators for us in the areas of mobile strep detection, mobile virus detection and other related areas including breath sample conditioning methodologies. The partnership gives us access to world-class expertise and skill in the field of personalized modeling..

We are working in conjunction with Nanobeak, LLC, a strategic partner, as well as NASA, to develop a mobile app to be used in connection with our sensor that will enable law enforcement to screen for marijuana use and deliver in-the-moment results to the officer’s smartphone, tablet or laptop in the field. Given the increase of marijuana legalization and decriminalization efforts by a growing number of states, we have made the development of a law enforcement sensor the short-term priority. There is a growing need on the part of law enforcement across the country for a portable sensor to detect marijuana abuse and impaired driving. We also plan to incorporate alcohol detection along with the marijuana sensing capability in one device so that law enforcement can have the capability to detect both alcohol (DUI breathalyzer) and marijuana abuse in a single device. The law enforcement device offers a quicker path to market based on reduced testing and regulatory requirements as compared to a medical diagnostic device.

Regulatory Approval

Our products as well as our research and development activities are regulated by numerous governmental authorities, principally the U.S Food and Drug Administration (FDA), as well as state and foreign regulatory agencies.

In the US, we believe that the medical diagnostic devices will be classified by the FDA as Class II medical devices and require clearance through a Form 510K. There can be no assurance that the FDA will provide marketing clearance for the device.

Manufacturing, Distribution, Sales

We intend to outsource manufacturing, distribution and sales but we have not entered into any definitive agreements for these functions.

Competition

We intend to compete with other detection devices by offering products that have enhanced value, ease of use, simple functionality, compatibility with various platforms, reliability, attractive price and are high in quality. The Company also believes its intellectual property provides an advantage over current competitors.

Disease Screening

There are a variety of methods to screen for the presence of disease. We are focused on non-invasive, point of care diagnostics.

Following years of research, a number of companies are now in prototype phase with devices that can test the chemical compounds in a person’s breath and identify the early stages of disease. Entry to this market is expected to continue and sharply rise as more prototypes emerge and begin to gain market entry with commercialized products. While companies in development tend to be small and privately owned, there has been entry by larger publicly owned companies that have greater financial reserves, distribution channels and more experience in commercialization. Acquisitions and collaborations by and companies seeking a competitive advantage also affect the competitive environment. This is a global market, evidenced by the emergence of companies bringing competitive solutions from different parts of the world.

New competitors may emerge and may develop products and capabilities which compete directly with our products. No assurance can be given that we will be successful in competing in the industries identified or in other industries that would benefit from our technology.

Customers for our medical diagnostic products is expected to include health care providers such as medical doctors, nurse practitioners and physician assistants.

Narcotics Screening

There are currently a variety of breathalyzer smartphone apps which essentially focus on alcohol detection. We are developing devices to distinguish between alcohol and narcotics and screen for a variety of narcotics both legal and illicit.

Making up the narcotic detection space are both domestic and international organizations that range from small, privately held companies to larger companies that include an array of diagnostic narcotics solutions. Although this market is more developed than disease detection, the space is dominated by a few key players making the possibility for new entrants feasible. Because toxicology screens are the most common type of narcotics testing products on the market, we believe that advanced technology that both detects and monitors discrete drug levels in an individual’s system through exhalation will cause this market to expand. The consumer market for mobile applications which provide detection and ongoing monitoring capabilities is anticipated to be significant.

Customers for our product will include the different areas of law enforcement as well as the different areas of professional and amateur sports. Corporations are also a target area for the narcotics screening technology.

Employees

We outsource all of our non-executive functions to Nanobeak, LLC. As of the date of this filing Nanobeak has 18 employees and consultants, both full and part time, most of which are shared with NASA and other contractors. The employees are not presently covered by any collective bargaining agreement.




 



Presentation: Thursday, May 18 – 10:35 AM – 10:45 AM:  http://unbelievable.very-good-idea.com/watch.php?vid=9d62b79ea

3 Columbus Circle, 15th Floor, New York, NY 10019
Phone: (212) 520-4950 | www.nanobeak.com
Category: Chemical Sensor Technology
Innovation: Nanobeak

 



Charts:






 
 

SureTrader
Interactive Brokers Advertisement
VNTH
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#14138  Sticky Note http://unbelievable.very-good-idea.com/mobile/watch.php?vid=9d62b79ea gater 06/16/17 08:14:58 AM
#13939  Sticky Note $VNTH 122page SEC Filing (5/05/17)...not your average sub-penny. Dr G Bucks 05/30/17 08:05:55 PM
#15194   What? It can't be! A SERIES ShizlDizl 12/13/17 04:12:00 PM
#15193   Let’s some news here finally ThoughtPower 12/13/17 08:24:49 AM
#15192   Hey GC - Which heavy hitters? Baconmaker 12/13/17 12:49:20 AM
#15191   MSGI? Did someone mention MSGI? Baconmaker 12/13/17 12:44:58 AM
#15190   Makes sense that the new venture as a DoingHomework 12/12/17 12:02:49 PM
#15189   Groman, Swan, then Nanobeak ptcgolf 12/12/17 11:52:34 AM
#15188   Groman...or...Nanobeak? Who is majority owner of VNTH? DoingHomework 12/12/17 11:37:34 AM
#15187   More than likely a sibling, one where a ptcgolf 12/12/17 11:31:45 AM
#15186   Answer: Unknown. NOT a legal parent of VNTH? ShizlDizl 12/12/17 09:49:47 AM
#15185   Interesting I don’t know but it sure looks JUST WAITING 12/12/17 09:09:38 AM
#15184   I assume another subsidiary, or joint venture with Dr G Bucks 12/12/17 08:39:26 AM
#15183   Yeah, I know that. What is Nanobeak Biotech then? gater 12/12/17 08:34:01 AM
#15182   Nanobeak is the private, parent company of $VNTH Dr G Bucks 12/12/17 08:31:51 AM
#15181   Has anyone noticed that on Jeremy's LinkedIn page gater 12/12/17 08:29:53 AM
#15180   .0007s getting tickled, not much left! Dr G Bucks 12/11/17 11:36:21 AM
#15178   No PM friend ..I have not done any kzivann 12/09/17 07:04:15 AM
#15177   2 millions shares? ThoughtPower 12/08/17 05:43:58 PM
#15176   I love the smell of VNTH dilution! ShizlDizl 12/08/17 12:06:34 PM
#15175   MM's walked us down to 4's and now GC Investments 12/07/17 04:18:26 PM
#15174   Something is brewing behind the scenes here. GC Investments 12/07/17 04:18:02 PM
#15173   VNTH is going to pop any day now! GC Investments 12/07/17 04:17:38 PM
#15172   Calm before the STORM! Dr G Bucks 12/06/17 07:44:04 AM
#15171   broke 50-day and 100-day moving averages, with firm The Sub-Penny Shaman 12/05/17 08:20:53 AM
#15170   Price Targets: .0013/.0018/.0027/.0035 The Sub-Penny Shaman 12/05/17 08:18:49 AM
#15169   believe you are right. my opinion will be The Sub-Penny Shaman 12/05/17 08:15:32 AM
#15168   strong bid support from 0005-0006, and volume picking The Sub-Penny Shaman 12/05/17 08:13:43 AM
#15167   We’re due here for an update ThoughtPower 12/05/17 08:08:02 AM
#15166   Dilutive MMs off the Ask...let the games begin!!! $vnth Dr G Bucks 12/05/17 07:59:52 AM
#15165   $VNTH primed for PennyLand Dr G Bucks 12/05/17 07:35:08 AM
#15164   Bounce is imminent! $VNTH Dr G Bucks 12/05/17 07:34:47 AM
#15163   6's are acting as support right now. 7's GC Investments 12/05/17 01:35:33 AM
#15162   Let's see if we can make this run GC Investments 12/05/17 01:34:59 AM
#15161   Getting in at trips is still a great GC Investments 12/05/17 01:22:03 AM
#15160   VNTH is one of the most underrated stocks GC Investments 12/05/17 01:21:29 AM
#15159   Those who loaded up on 4's and 5's GC Investments 12/05/17 01:20:59 AM
#15158   VNTH is partnered with NASA and has a GC Investments 12/05/17 01:20:25 AM
#15157   Over 6 million in volume today...the most in GC Investments 12/05/17 01:19:15 AM
#15156   VNTH is backed by some very heavy hitters GC Investments 12/05/17 01:18:02 AM
#15155   If we can break out of trips by GC Investments 12/05/17 12:53:29 AM
#15154   Now it's time to see us break out GC Investments 12/05/17 12:52:50 AM
#15153   Strong hands let the stock die down for GC Investments 12/05/17 12:52:06 AM
#15152   VNTH might be making its long awaited run finally. GC Investments 12/05/17 12:51:43 AM
#15151   This is the first time we have closed GC Investments 12/05/17 12:50:49 AM
#15150   Lots of volume today is a good indicator GC Investments 12/05/17 12:48:58 AM
#15149   VNTH is going to blow any day now. GC Investments 12/05/17 12:42:26 AM
#15148   Solid Bid Support. Very low volatility with $VNTH Dr G Bucks 12/04/17 04:03:49 PM
#15147   Why does it go from .0008 to .0006? gater 12/04/17 01:37:24 PM
#15146   By 2018 there will be no more trips Dr G Bucks 12/04/17 10:34:23 AM
#15145   This keep on inching up not long and JUST WAITING 12/04/17 10:32:31 AM
#15144   $VNTH .0008s are up! And not much left!! Glta Dr G Bucks 12/04/17 09:56:40 AM
PostSubject